The candidate vaccine developed by the Oxford University and the Serum Institute of India is among the two such vaccines added to the ongoing Ebola clinical trials, according to a World Health Organisation (WHO) statement, making it the first addition of candidate vaccines to the trials specifically targeting the Bundibugyo virus that has caused the current Ebola outbreak in the Democratic Republic of the Congo (DRC).
Candidate vaccine by SII, Oxford varsity to join Ebola trial: WHO
Published ·

Keep reading
Related stories







